Absolute lymphocyte count and risk of short-term infection in patients with immune thrombocytopenia
详细信息 查看全文
- 作者：Ming-Hung Hu (1) (3) (5)
Yuan-Bin Yu (1) (3)
Yu-Chung Huang (1) (3) (4)
Jyh-Pyng Gau (1) (3)
Liang-Tsai Hsiao (1) (3)
Jin-Hwang Liu (1) (3)
Ming-Huang Chen (1) (3)
Tzeon-Jye Chiou (2) (3)
Po-Min Chen (1) (3)
Cheng-Hwai Tzeng (1) (3)
Chun-Yu Liu (1) (3) - 关键词：Immune thrombocytopenia (ITP) ; Absolute lymphocyte count (ALC) ; Lymphopenia ; Infection
- 刊名：Annals of Hematology
- 出版年：2014
- 出版时间：June 2014
- 年：2014
- 卷：93
- 期：6
- 页码：1023-1029
- 全文大小：
- 参考文献：1. Portielje JE, Westendorp RG, Kluin-Nelemans HC et al (2001) Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 97:2549-554 CrossRef
2. Mazzucconi MG, Fazi P, Bernasconi S et al (2007) Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 109:1401-407 CrossRef
3. Norgaard M, Jensen AO, Engebjerg MC et al (2011) Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Blood 117:3514-520 CrossRef
4. Daou S, Federici L, Zimmer J et al (2008) Idiopathic thrombocytopenic purpura in elderly patients: a study of 47 cases from a single reference center. Eur J Intern Med 19:447-51 CrossRef
5. Huang YC, Liu CJ, Liu CY et al (2011) Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma. Ann Hematol 90:1145-151 CrossRef
6. Siddiqui M, Ristow K, Markovic SN et al (2006) Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol 134:596-01 CrossRef
7. Cox MC, Nofroni I, Ruco L et al (2008) Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma 49:1745-751 CrossRef
8. George JN, Woolf SH, Raskob GE et al (1996) Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 88:3-0
9. Neunert C, Lim W, Crowther M et al (2011) The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 117:4190-207 CrossRef
10. Godeau B, Chevret S, Varet B et al (2002) Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet 359:23-9 CrossRef
11. Cheng Y, Wong RS, Soo YO et al (2003) Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 349:831-36 CrossRef
12. Figueroa M, Gehlsen J, Hammond D et al (1993) Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med 328:1226-229 CrossRef
13. Boruchov DM, Gururangan S, Driscoll MC et al (2007) Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood 110:3526-531 CrossRef
14. Ghanima W, Godeau B, Cines DB et al (2012) How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood 120:960-69 CrossRef
15. Huang JJ, Jiang WQ, Lin TY et al (2011) Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Ann Oncol 22:149-55 CrossRef
16. Hung MH, Yu YB, Hsiao LT et al (2013) Absolute lymphocyte count predicts response to rituximab-containing salvage treatment for relapsed/refractory B-cell non-Hodgkin’s lymphoma with prior rituximab exposure. J Chin Med Assoc 76:195-00 CrossRef
17. Oki Y, Yamamoto K, Kato H et al (2008) Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients-survival benefit from rituximab. Eur J Haematol 81:448-53 CrossRef
18. Rodeghiero F, Stasi R, Gernsheimer T et al (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113:2386-393 CrossRef
19. Panitsas FP, Theodoropoulou M, Kouraklis A et al (2004) Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 103:2645-647 CrossRef
20. Wang T, Zhao H, Ren H et al (2005) Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica 90:914-23
21. Semple JW, Provan D (2012) The immunopathogenesis of immune thrombocytopenia: T cells still take center-stage. Curr Opin Hematol 19:357-62 CrossRef
22. Semple JW (1998) Immunobiology of T helper cells and antigen-presenting cells in autoimmune thrombocytopenic purpura (ITP). Acta Paediatr Suppl 424:41-5 CrossRef
23. Nishimoto T, Satoh T, Takeuchi T et al (2012) Critical role of CD4(+)CD25(+) regulatory T cells in preventing murine autoantibody-mediated thrombocytopenia. Exp Hematol 40:279-89 CrossRef
24. Aboul-Fotoh Lel M, Abdel Raheem MM, El-Deen MA et al (2011) Role of CD4+ CD25+ T cells in children with idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 33:81-5 CrossRef
25. Johnsen J (2012) Pathogenesis in immune thrombocytopenia: new insights. Hematology Am Soc Hematol Educ Program 2012:306-12
26. Sakakura M, Wada H, Tawara I et al (2007) Reduced Cd4+ Cd25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res 120:187-93 CrossRef
27. Semple JW (2002) Immune pathophysiology of autoimmune thrombocytopenic purpura. Blood Rev 16:9-2 CrossRef
28. Cines DB, Bussel JB, Liebman HA et al (2009) The ITP syndrome: pathogenic and clinical diversity. Blood 113:6511-521 CrossRef
29. Blatt SP, Lucey CR, Butzin CA et al (1993) Total lymphocyte count as a predictor of absolute CD4+ count and CD4+ percentage in HIV-infected persons. JAMA 269:622-26 CrossRef
30. Shapiro NI, Karras DJ, Leech SH et al (1998) Absolute lymphocyte count as a predictor of CD4 count. Ann Emerg Med 32:323-28 CrossRef
31. Napoli AM, Fischer CM, Pines JM et al (2011) Absolute lymphocyte count in the emergency department predicts a low CD4 count in admitted HIV-positive patients. Acad Emerg Med 18:385-89 CrossRef
32. Napoli AM, Maughan B, Murray R et al (2013) Use of the relationship between absolute lymphocyte count and CD4 count to improve earlier consideration of pneumocystis pneumonia in HIV-positive emergency department patients with pneumonia. J Emerg Med 44:28-5 CrossRef
33. Meibohm B, Derendorf H, Mollmann H et al (1999) Mechanism-based PK/PD model for the lymphocytopenia induced by endogenous and exogenous corticosteroids. Int J Clin Pharmacol Ther 37:367-76
34. Zweiman B, Atkins PC, Bedard PM et al (1984) Corticosteroid effects on circulating lymphocyte subset levels in normal humans. J Clin Immunol 4:151-55 CrossRef
35. Ginsburg C, Guillevin L, Sauvaget F et al (1993) Systemic diseases treated by corticoids, plasma exchange and cyclophosphamide: infectious complications and lymphopenia. Ann Med Interne (Paris) 144:15-9
36. Craddock CG (1978) Corticosteroid-induced lymphopenia, immunosuppression, and body defense. Ann Intern Med 88:564-66 CrossRef
37. Pamuk GE, Pamuk ON, Baslar Z et al (2002) Overview of 321 patients with idiopathic thrombocytopenic purpura. Retrospective analysis of the clinical features and response to therapy. Ann Hematol 81:436-40 CrossRef
38. Boren E, Gershwin ME (2004) Inflamm-aging: autoimmunity, and the immune-risk phenotype. Autoimmun Rev 3:401-06 CrossRef
39. Prelog M (2006) Aging of the immune system: a risk factor for autoimmunity? Autoimmun Rev 5:136-39 CrossRef
40. Hasler P, Zouali M (2005) Immune receptor signaling, aging, and autoimmunity. Cell Immunol 233:102-08 CrossRef
41. Cohen YC, Djulbegovic B, Shamai-Lubovitz O et al (2000) The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 160:1630-638 CrossRef - 作者单位：Ming-Hung Hu (1) (3) (5)
Yuan-Bin Yu (1) (3)
Yu-Chung Huang (1) (3) (4)
Jyh-Pyng Gau (1) (3)
Liang-Tsai Hsiao (1) (3)
Jin-Hwang Liu (1) (3)
Ming-Huang Chen (1) (3)
Tzeon-Jye Chiou (2) (3)
Po-Min Chen (1) (3)
Cheng-Hwai Tzeng (1) (3)
Chun-Yu Liu (1) (3)
1. Division of Haematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Beitou Dist., Taipei City, 11217, Taiwan, Republic of China
3. National Yang-Ming University School of Medicine, Taipei, Taiwan, Republic of China
5. Division of Haematology and Oncology, Department of Medicine, Cardinal Tien Hospital, New Taipei City, Taiwan
4. Division of Haematology and Oncology, Department of Medicine, Taoyuan Veterans Hospital, Taoyuan City, Taiwan, Republic of China
2. Division of Transfusion Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China - ISSN：1432-0584
文摘
Patients with immune thrombocytopenia (ITP) may be at increased risk of infection because of the steroids and other immunosuppressive agents used in its treatment. This study aimed to identify events that are associated with infection within 6?months of diagnosis and the impact that infection has on survival. We retrospectively evaluated 239 patients (107 men, 132 women; median age 61?years) diagnosed between January 1997 and August 2011. Every patient received steroid treatment according to the platelet count and the extent of bleeding. Logistic regression analysis was used to identify risk factors associated with the development of infection within 6?months of ITP being diagnosed. Sixty-two patients (25.9?%) developed an infection within 6?months of diagnosis. Multivariate analysis revealed that a lower absolute lymphocyte count (ALC) at diagnosis (<1?×-09/l) was an independent risk factor for infection (P--.039; 95?% confidence interval, 1.033-.599; odds ratio, 1.928). The time to infection event is significant shorter in those of low ALC, compared with those of higher ALC (P--.032). Furthermore, the 1-year mortality rate after ITP diagnosis was significantly higher in those patients who developed an infection (P--.001). ITP patients with a low absolute lymphocyte count at diagnosis have an increased risk of infection, and those who develop infections have lower 1-year survival.